CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 21 enrolled
Drug / intervention
30% supramolecular salicylic acid +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06307223
NCT06307223Phase 4Completed

Efficacy and Safety of 30% Supramolecular Salicylic Acid Combined With Supramolecular Active Zinc in the Treatment of Malassezia Folliculitis

Second Affiliated Hospital of Xi'an Jiaotong University·interventional·Posted Mar 12, 2024·Updated Mar 12, 2024

In Brief

A Phase 4 clinical trial evaluating 30% supramolecular salicylic acid and supramolecular active zinc for Malassezia Folliculitis. Completed, enrolled 21 participants across 1 site.

Detailed Summary

Malassezia folliculitis is a common dermatological disorder. While antifungal agents generally demonstrate efficacy in application, the prevalence of recurrence and drug resistance remains a common occurrence. Supramolecular salicylic acid represents a novel class of superficial chemical peel agents, exhibiting keratolytic, anti-inflammatory, and bacteriostatic properties. Zinc pyrithione has broad spectrum antibacterial, antifungal, and anti-inflammatory effects. In the present study, investigators evaluated the clinical efficacy of topical application of supramolecular salicylic acid in combination with zinc pyrithione for the treatment and prevention of Malassezia folliculitis recurrence. All data are recorded and compared after the end of the experiment. The enrolled patients received daily application of topical supramolecular active zinc anti-dandruff lotion, in conjunction with weekly application of 30% supramolecular salicylic acid, for a duration of 8 weeks. Lesion counts, Malassezia detection, clinical symptom scores, patient satisfaction, and side effects were recorded at each visit till the week 12.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesChina
Collaborators--

Timeline

Phase 4CompletedFinished
2023202420252026
First PostedMar 12, 2024
Enrollment StartJun 7, 2022
Primary CompletionSep 20, 2023
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 2.3 years ago

Interventions

30% supramolecular salicylic aciddrug

The patients received weekly application of 30% supramolecular salicylic acid for a duration of 8 weeks.

supramolecular active zincdrug

The patients received daily application of topical supramolecular active zinc anti-dandruff lotion for a duration of 8 weeks.